Miami
Thyroid Oncology Symposium

April 9-10, 2021

Featured Workshops
Advances in Radioactive Iodine Theranostics
Advances in Molecular Diagnostics of Thyroid Nodules
We welcome you to the 4th Miami Thyroid Oncology Symposium to discuss the science and art of care of patients with thyroid nodules and cancer. The paradigm is “Personalized Medicine” by means of “Molecular Theranostics”. Our approach to thyroid nodules and thyroid cancer has expanded beyond conventional diagnostics and therapeutic interventions. A broad catalogue of genomic and epigenomic markers associated with thyroid cancer is now available and are in clinical use. The risk stratification systems that are critical for initial surgical treatment and subsequent use of radioactive iodine treatment will rely more and more on distinct molecular markers, and less on traditional parameters. Genomics with molecular pathology and molecular imaging reflect the true biologic nature of the different cancer types currently defined by conventional morphologic features. The tumor differentiation/de-differentiation and clinical behavior for each individual cancer are now being defined by molecular characteristics, in addition to standard histopathology. The Miami Thyroid Oncology Symposium offers a platform for in depth discussions of the science of thyroid cancer diagnosis and treatment in this new paradigm. It is a unique scientific forum where practicing physicians learn how to adopt and incorporate the new treatment tools and techniques into their daily practice.

The symposium is a two-day program. There will be two half-day workshops on the first day of the symposium; Advances in Radioactive iodine (RAI) Theranostics and Advances in Molecular Diagnostics of Thyroid Nodules, which will provide in depth overview of these specific areas and address current controversies. The plenary session on the second day of the symposium on Saturday, April 10, 2021 is entitled Frontiers in Thyroid Oncology. This session brings together world renowned experts presenting and discussing the state of the Art in Thyroid cancer diagnosis and treatment.

The 2021 Miami Thyroid Oncology Symposium (MTOS) will be held in a virtual format due to the unprecedented times we are experiencing. We are committed to uphold the high-quality symposium standards we have built in the prior years. We are indebted to our world-renowned faculty for taking part in this exciting new scientific platform. We also hope to expand our attendance by reaching to a larger national and international audience via the virtual format.
Symposium Faculty

**Seza Gulec, MD, FACS, FACNM, Symposium Co-Director**  
Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine  
President Elect, Medical staff, Aventura Hospital and Medical Center, Miami FL  
President and Chairman of the Board, Miami Cancer Research Center

**Yuri E. Nikiforov, MD, PhD, Symposium Co-Director**  
Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology  
University of Pittsburgh Medical Center, Pittsburgh, PA

**Marina N. Nikiforova, MD**  
Professor, Department of Pathology, Director, Molecular & Genomic Pathology Laboratory  
University of Pittsburgh Medical Center, Pittsburgh, PA

**James A. Fagin, MD**  
Division Head, Subspecialty Medicine, Memorial Sloan Kettering Cancer Center  
Professor of Medicine, Weill Cornell Medical College, New York, NY

**R. Michael Tuttle, MD**  
Acting Chief, Endocrinology Service, Memorial Sloan Kettering Cancer Center  
Professor of Medicine, Weill Cornell Medical College, New York, NY

**Maria Cabanillas, MD**  
Professor and the Faculty Director of Clinical Research  
Department of Endocrine Neoplasia, MD Anderson, Houston, TX

**Markus Luster, MD**  
Professor of Nuclear Medicine  
Department of Nuclear Medicine, University Hospital Marburg, Germany

**Victor J Bernet, MD**  
Mayo Clinic College of Medicine, Jacksonville, FL USA

**Bennett Greenspan, MD, FACNP**  
Chairman of Advisory Board and Senior Associate Researcher  
Miami Cancer Research Center, Miami, FL

**Sarah Mayson, MD**  
Associate Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes,  
University of Colorado School of Medicine, Aurora, CO

**Douglas Van Nostrand, MD, FACP, FACNP**  
Director of Nuclear Medicine at MedStar Health Research Institute  
Professor of Medicine at Georgetown University Medical Center in Washington, DC
08:00 Welcome and Introduction  
Dr. Seza Gulec

08:00-08:30 Molecular Basis of RAI Theranostics  
- Brief History: Hertz, Fitzgerald, Beirwaltes, Mazafferri Trail  
- Tumor Biology and RAI Physiology: Iodine Metabolism and RAI kinetics, MAPK and TDS  
Dr. Seza Gulec

08:30-09:00 RAI Avidity and Responsiveness  
- Definitions and Classifications: RAI Refractory Disease, RAI Resistant Disease, RAI Indifferent Cancer  
Dr. Douglas Van Nostrand

09:00-09:30 RAI Imaging Performance  
- Brief Physics: Sensitivity/Specificity/Spatial Resolution:  
- Clinical Imaging: Comparison of Isotopes and Scanning Techniques  
- Comparison of Pre-treatment and Post-treatment Imaging  
Dr. Markus Luster

09:30-10:00 Improving Diagnostic and Therapeutic Profile of RAI  
- Evaluation of Response to RAI Treatment  
- TSH stimulation  
- Clinical Trials  
Dr. Douglas Van Nostrand

10:00-10:30 Theranostic Power of RAI  
- Biologic, Anatomic, Technical Challenges and Solutions  
- Modulation of MAPK Pathway  
- I-124 PET/CT Imaging and Dosimetry  
Dr. Seza Gulec

10:30-11:00 Break  
Please visit our Sponsors during the break by clicking here!

11:00-11:30 Appropriate Use Criteria for RAI Imaging and Treatment  
- Dosage and Protocol Selection for RAI Imaging and Therapy  
- Adverse Events from RAI: Facts and Fiction  
Dr. Bennett Greenspan

11:30-12:00 Thinking Differently About “DTC” in the Genomic Paradigm  
- Redefinition of “Differentiated Thyroid Cancer”  
- Molecular Theranostics-guided RAI Imaging and Treatment  
Dr. Seza Gulec

12:00 Closing Remarks and Adjourn  
*all times listed above are in Eastern Time (ET)*
13:00 Welcome and Introduction
Dr. Yuri Nikiforov

13:00-13:30 Molecular Landscape of Thyroid Nodules and Cancer
- Genetic Landscape of Main Types of Thyroid Cancer
- Main Types of Genetic Alterations: Mutations, Gene Fusions, Copy Number Changes
Dr. Yuri Nikiforov

13:30-14:00 Principles of Molecular Diagnostics of Thyroid Nodules
- Next Generation Sequencing
- RNA Sequencing, mRNA and miRNA
- Accuracy of detecting molecular alterations
- Building a Comprehensive Diagnostic Test Platform
Dr. Marina Nikiforova

14:00-14:30 The Diagnostic Performance of Molecular Tests
- Clinical Molecular Test Portfolio
- Determination and Comparisons of Diagnostic Performances
- Understanding Molecular Test Reports
Dr. Sarah Mayson

14:30-15:00 Break
Please visit our Sponsors during the break by clicking here!

15:00-15:30 New Genetic Markers for Thyroid Nodules
- GLIS fusions, MEK1 mutations, copy number alterations and other recently discovered cancer markers
- Genetic markers of thyroid cancer risk and impact on patient management
Dr. Marina Nikiforova

15:30-16:00 Genetic Markers Associated with Familial Syndromes
- DICER1, PTEN, RET mutations and corresponding familial syndromes
Dr. Yuri Nikiforov

16:00-17:00 Case Discussions/Q&A with Panelists
- Impact of molecular markers on clinical management of patients with thyroid nodules
Drs. Seza Gulec, Sarah Mayson, Yuri Nikiforov, and Marina Nikiforova

17:00 Closing Remarks and Adjourn

*all times listed above are in Eastern Time (ET)
PLENARY SESSION
Frontiers in Thyroid Oncology
Saturday, April 10, 2021 | 8:00 – 17:00

08:00  Welcome and Introduction
Dr. Yuri Nikiforov and Dr. Seza Gulec

08:00-08:40  Genomic predictors of sensitivity and resistance to radioiodine therapy
Dr. James Fagin

08:40-09:20  Perioperative Risk Stratification in Thyroid Cancer
Dr. R. Michael Tuttle

09:20-10:00  Molecular Approaches to Perioperative Risk Stratification
Dr. Yuri Nikiforov

10:00-10:40  Thyroidectomy: Surgical, Nuclear and Molecular Insights
Dr. Seza Gulec

10:40-11:00  AM Break
Please visit our Sponsors during the break by clicking here!

11:00-11:30  Postoperative RAI Imaging and Treatment
Dr. Victor Bernet

11:30-12:00  Panel Discussion- Q&A
Drs. James Fagin, R. Michael Tuttle, Seza Gulec, Victor Bernet, and Yuri Nikiforov

12:00-13:00  Lunch Break
Please visit our Sponsors during the lunch break by clicking here!

13:00-13:30  Clinical Considerations in Remnant Ablation and Adjuvant Treatment
Dr. Markus Luster

13:30-14:00  Targeted Therapies For Thyroid Cancer: Modulation of MAPK Output
Dr. James Fagin

14:00-14:30  Targeting Gene Fusions In Thyroid Cancer
Dr. Maria Cabanillas

14:30-15:00  Radioactive Iodine Imaging and Therapy in 2021
Dr. Douglas Van Nostrand

15:00-15:30  Molecular-guided Treatment of ATC
Dr. Maria Cabanillas

15:30-16:00  PM Break
Please visit our Sponsors during the break by clicking here!

16:00-17:00  Panel Discussion- Q&A
Drs. Markus Luster, James Fagin, Maria Cabanillas, Douglas Van Nostrand, and Seza Gulec

17:00  Closing Remarks and Adjourn

*all times listed above are in Eastern Time (ET)
Organizing Committee

Seza Gulec, MD, FACS, FACNM, Symposium Co-Director
Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President Elect, Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Yuri E. Nikiforov, MD, PhD, Symposium Co-Director
Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA

J. Paul Perales-Villarroel, MD, Symposium Administrator
Chief Operating Officer,
Miami Cancer Research Center, Miami, FL

Marisabel Davalos, MSEd., CIP, CHRC®, CME Coordinator
Chief Compliance Officer,
Miami Cancer Research Center, Miami, FL

Lindsey Tolino, MBA, Symposium Coordinator
Project Manager
University of Pittsburgh Medical Center Division of Molecular & Genomic Pathology

Deidra Eberle, CMP, Symposium Coordinator
Meeting Planner
American College of Surgeons

Anthony McGoron, PhD, Symposium Senior Administrator
Professor of Biomedical Engineering and Associate Dean for Academic Affairs,
Florida International University College of Engineering and Computing
Vice President, Miami Cancer Research Center, Miami, FL
Miami Thyroid Oncology Symposium is organized by the Miami Cancer Research Center (MCRC). MCRC is a scientific and charitable organization that performs and supports cancer research, organizes educational events and provides support for cancer care at institutional and individual levels. The mission of the MCRC is to take part in the global fight against cancer through research, education and patient care support.

The symposium will offer a maximum of 16 AMA PRA Category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the meeting. CME’s will be awarded from the Dade County Medical Association (DCMA), which is accredited by the Accreditation Council for Continuing Medical Education (ACCME).

The Miami Dade County Medical Association (MDCMA) is the providing Joint Sponsorship for CME for the 4th Annual Miami Thyroid Oncology Symposium (MTOS). You will be required to complete evaluations for full accreditation for participating in the 4th Annual Miami Thyroid Oncology Symposium on April 9-10th, 2021. Once the symposium begins, please expect to receive email instructions on how to complete the electronic Evaluation Forms to claim CME credit for each lecture you participated in.

**Please note: Each lecture has a separate evaluation link, and you are required to complete a short evaluation for each lecture you participated in.**

Because these are electronic evaluations, your data will be automatically captured and delivered to the MDCMA CME office upon completion. The MDCMA will cross reference the digital data collected when you joined and left the meeting to confirm that you participated in each lecture for which you plan to claim credit(s). Once the MDCMA receives your evaluation form(s), total hour(s) completed will be reported to the CE broker (for MTOS), who will then distribute CME Certificates.

**Using the link provided, participants/attendees must complete all evaluations by April 16, 2021. CME certificates will not be issued for evaluations submitted after the deadline.**

**SYMPOSIUM SUPPORT**
*(sponsorship information continues on the next page)*

**GOLD LEVEL**
- Eisai, Inc.
- Jubilant Radiopharma
- Sonic Healthcare USA
- Thermo Fisher Scientific

**SILVER LEVEL**
- Bayer
- Ethicon

_The Symposium has also been made possible by a generous Educational Grant from Eli Lilly_

Miami Cancer Research Center | miamicancerresearch.org
Questions? Contact Deidra Eberle, CMP (MTOS Meeting Planner) | deberle@facs.org
The Miami Cancer Research Center would like to extend their gratitude to the following companies for making this year’s 4th Annual Miami Thyroid Oncology Symposium possible. Thank you for the continued supporting and helping us fulfill our commitment in furthering the science of thyroid cancer towards the new frontiers.

**Gold Level**

<table>
<thead>
<tr>
<th>Company</th>
<th>Contact Details</th>
<th>Website</th>
</tr>
</thead>
</table>
| Eisai Inc.               | Contact: Amy Four  
                          Email: Amy_Four@eisai.com  
                          Website: https://www.EisaiOncCongresses.com/mtos | ![Eisai](Eisai.png)  
  Click here to view Eisai Inc’s promotional video. |
| Jubilant Radiopharma     | Contact: Suzanne Bissonnette  
                          Email: SBissonnette@jubl.com  
                          Website: www.jubilantradiopharma.com  
                          ![Jubilant Radiopharma](JubilantRadiopharma.png) | ![Jubilant Radiopharma](JubilantRadiopharma.png) |
| Sonic Healthcare USA     | Contact Email: thyroseq@sonichealthcare.com  
                          Website: www.thyroseq.com  
                          ![Thyroseq](Thyroseq.png)  
  Click here to view Sonic Healthcare’s promotional video. | ![Thyroseq](Thyroseq.png) |
| Thermo Fisher Scientific | Contact: Celia Garcia  
                          Email: celia.garcia@thermofisher.com  
                          Website: www.thermofisher.com  
                          ![Thermo Fisher Scientific](ThermoFisherScientific.png)  
  Click here to view Thermo Fisher’s promotional video. | ![Thermo Fisher Scientific](ThermoFisherScientific.png) |

**Silver Level**

<table>
<thead>
<tr>
<th>Company</th>
<th>Contact Details</th>
<th>Website</th>
</tr>
</thead>
</table>
| Bayer   | Contact: Carlos Forment and Sandy Donaldson  
                          Email: carlos.forment@bayer.com; Sandra.Donaldson@bayer.com  
                          Website: www.bayer.us  
                          ![Bayer](Bayer.png)  
  Click here to learn more about VITRAKVI® (larotrectinib) | ![Bayer](Bayer.png) |
| Ethicon | Contact: Christina Bustillo  
                          Email: cbustil1@its.jnj.com  
                          Website: https://jnj.showpad-solutions.com/ | ![Ethicon](Ethicon.png) |

The Symposium has also been made possible by a generous Educational Grant from Eli Lilly